Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.32
BMRN's Cash to Debt is ranked lower than
77% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. BMRN: 1.32 )
Ranked among companies with meaningful Cash to Debt only.
BMRN' s 10-Year Cash to Debt Range
Min: 0.12  Med: 1.17 Max: No Debt
Current: 1.32
Equity to Asset 0.66
BMRN's Equity to Asset is ranked lower than
53% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BMRN: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
BMRN' s 10-Year Equity to Asset Range
Min: -0.66  Med: 0.57 Max: 0.97
Current: 0.66
-0.66
0.97
F-Score: 2
Z-Score: 10.82
M-Score: -1.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -16.48
BMRN's Operating margin (%) is ranked higher than
62% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. BMRN: -16.48 )
Ranked among companies with meaningful Operating margin (%) only.
BMRN' s 10-Year Operating margin (%) Range
Min: -1075  Med: -29.30 Max: 13.41
Current: -16.48
-1075
13.41
Net-margin (%) -20.35
BMRN's Net-margin (%) is ranked higher than
60% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. BMRN: -20.35 )
Ranked among companies with meaningful Net-margin (%) only.
BMRN' s 10-Year Net-margin (%) Range
Min: -1025  Med: -32.15 Max: 54.7
Current: -20.35
-1025
54.7
ROE (%) -9.74
BMRN's ROE (%) is ranked higher than
65% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. BMRN: -9.74 )
Ranked among companies with meaningful ROE (%) only.
BMRN' s 10-Year ROE (%) Range
Min: -751.65  Med: -14.97 Max: 39.6
Current: -9.74
-751.65
39.6
ROA (%) -6.15
BMRN's ROA (%) is ranked higher than
68% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. BMRN: -6.15 )
Ranked among companies with meaningful ROA (%) only.
BMRN' s 10-Year ROA (%) Range
Min: -76.62  Med: -8.96 Max: 18.88
Current: -6.15
-76.62
18.88
ROC (Joel Greenblatt) (%) -18.74
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. BMRN: -18.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -433  Med: -43.07 Max: 31.1
Current: -18.74
-433
31.1
Revenue Growth (3Y)(%) 9.20
BMRN's Revenue Growth (3Y)(%) is ranked higher than
63% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. BMRN: 9.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMRN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 9.60 Max: 97.7
Current: 9.2
0
97.7
EPS Growth (3Y)(%) 24.20
BMRN's EPS Growth (3Y)(%) is ranked higher than
79% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. BMRN: 24.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMRN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -0.95 Max: 36.5
Current: 24.2
0
36.5
» BMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BMRN Guru Trades in Q3 2014

Joel Greenblatt 3,885 sh (New)
Paul Tudor Jones 5,913 sh (New)
Steven Cohen 675,600 sh (+649.83%)
Manning & Napier Advisors, Inc 288,180 sh (+18.08%)
John Griffin 2,230,000 sh (+6.19%)
Frank Sands 12,098,628 sh (+1.45%)
PRIMECAP Management 8,043,918 sh (-0.25%)
Columbia Wanger 853,800 sh (-26.89%)
» More
Q4 2014

BMRN Guru Trades in Q4 2014

RS Investment Management 94,400 sh (New)
Louis Moore Bacon 56,100 sh (New)
Frank Sands 12,183,113 sh (+0.70%)
Frank Sands 12,183,113 sh (+0.70%)
John Griffin 2,230,000 sh (unchged)
Manning & Napier Advisors, Inc 288,180 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 8,016,518 sh (-0.34%)
Columbia Wanger 416,200 sh (-51.25%)
Steven Cohen 74,600 sh (-88.96%)
» More
Q1 2015

BMRN Guru Trades in Q1 2015

Signature Select Canadian Fund 18,300 sh (New)
Joel Greenblatt 4,195 sh (New)
Frank Sands 12,335,452 sh (+1.25%)
PRIMECAP Management 8,025,008 sh (+0.11%)
John Griffin 2,230,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Columbia Wanger Sold Out
Steven Cohen Sold Out
Louis Moore Bacon 27,500 sh (-50.98%)
RS Investment Management 33,900 sh (-64.09%)
» More
2015

BMRN Guru Trades in 2015

PRIMECAP Management 7,999,958 sh (-0.31%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.04
BMRN's P/B is ranked lower than
73% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. BMRN: 9.04 )
Ranked among companies with meaningful P/B only.
BMRN' s 10-Year P/B Range
Min: 3.68  Med: 6.87 Max: 28.5
Current: 9.04
3.68
28.5
P/S 25.97
BMRN's P/S is ranked lower than
62% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. BMRN: 25.97 )
Ranked among companies with meaningful P/S only.
BMRN' s 10-Year P/S Range
Min: 3.37  Med: 15.49 Max: 89.57
Current: 25.97
3.37
89.57
EV-to-EBIT -160.25
BMRN's EV-to-EBIT is ranked lower than
465% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. BMRN: -160.25 )
Ranked among companies with meaningful EV-to-EBIT only.
BMRN' s 10-Year EV-to-EBIT Range
Min: -1611.4  Med: -50.05 Max: 67133.8
Current: -160.25
-1611.4
67133.8
Current Ratio 4.98
BMRN's Current Ratio is ranked higher than
54% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. BMRN: 4.98 )
Ranked among companies with meaningful Current Ratio only.
BMRN' s 10-Year Current Ratio Range
Min: 0.9  Med: 6.63 Max: 18.94
Current: 4.98
0.9
18.94
Quick Ratio 4.25
BMRN's Quick Ratio is ranked higher than
50% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BMRN: 4.25 )
Ranked among companies with meaningful Quick Ratio only.
BMRN' s 10-Year Quick Ratio Range
Min: 0.82  Med: 6.16 Max: 18.77
Current: 4.25
0.82
18.77
Days Inventory 520.82
BMRN's Days Inventory is ranked lower than
96% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. BMRN: 520.82 )
Ranked among companies with meaningful Days Inventory only.
BMRN' s 10-Year Days Inventory Range
Min: 106.92  Med: 514.36 Max: 917.29
Current: 520.82
106.92
917.29
Days Sales Outstanding 79.91
BMRN's Days Sales Outstanding is ranked lower than
63% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. BMRN: 79.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRN' s 10-Year Days Sales Outstanding Range
Min: 50.96  Med: 79.37 Max: 212.92
Current: 79.91
50.96
212.92

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 75.60
BMRN's Price/Net Current Asset Value is ranked lower than
96% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. BMRN: 75.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BMRN' s 10-Year Price/Net Current Asset Value Range
Min: 2.98  Med: 18.56 Max: 208.24
Current: 75.6
2.98
208.24
Price/Tangible Book 16.91
BMRN's Price/Tangible Book is ranked lower than
84% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. BMRN: 16.91 )
Ranked among companies with meaningful Price/Tangible Book only.
BMRN' s 10-Year Price/Tangible Book Range
Min: 2.15  Med: 7.33 Max: 103.23
Current: 16.91
2.15
103.23
Price/Projected FCF 30.41
BMRN's Price/Projected FCF is ranked lower than
87% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BMRN: 30.41 )
Ranked among companies with meaningful Price/Projected FCF only.
BMRN' s 10-Year Price/Projected FCF Range
Min: 19.71  Med: 28.46 Max: 234.29
Current: 30.41
19.71
234.29
Price/Median PS Value 1.68
BMRN's Price/Median PS Value is ranked lower than
66% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. BMRN: 1.68 )
Ranked among companies with meaningful Price/Median PS Value only.
BMRN' s 10-Year Price/Median PS Value Range
Min: 0.26  Med: 1.16 Max: 9.97
Current: 1.68
0.26
9.97
Earnings Yield (Greenblatt) (%) -0.60
BMRN's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. BMRN: -0.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMRN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 1.50 Max: 3.3
Current: -0.6
0.3
3.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 

More From Other Websites
Dwarfism Drug Brings Mixed Emotions for Little People, Parents Jul 02 2015
The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta -... Jul 02 2015
Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress -... Jul 01 2015
Should The Biotech Bubble Be Feared? Jun 30 2015
Sarepta Files Eteplirsen NDA, Secures $40M Debt Financing - Analyst Blog Jun 30 2015
BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog Jun 30 2015
​Sarepta CEO: Teamwork has been key to quick progress on Duchenne drug Jun 29 2015
BioMarin, Sarepta Muscular Dystrophy Drugs Progress Jun 29 2015
BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable... Jun 29 2015
BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable... Jun 29 2015
Sarepta Submits DMD Drug for FDA Approval Review Jun 29 2015
BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog Jun 26 2015
BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy... Jun 25 2015
BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy... Jun 25 2015
The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases Jun 25 2015
Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog Jun 24 2015
BioMarin CEO: Excited about dwarfism drug potential Jun 23 2015
5 Biotech Stocks to Trade for Gains Jun 23 2015
BioMarin Pharmaceutical (BMRN) Stock Is the 'Chart of the Day' Jun 22 2015
BioMarin Pharmaceutical Surges on Price Target Increase - Analyst Blog Jun 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK